Arca
Skip to content
Tools
Tools

Postpartum depression

Drug research and approvals for postpartum depression: what is recruiting, what Health Canada authorized, FDA orphan designations and EU medicines. See every condition.

As of Nov 21, 2026, 88 studies of postpartum depression are recruiting on ClinicalTrials.gov, Health Canada has authorized 4 drug trials for it since 2013, and the EU has 1 authorised medicine for it.

  • Recruiting worldwide: 88
  • Trials authorized in Canada: 4
  • FDA orphan approvals: 0
  • EU medicines: 1

Recruiting now

Newest posted first, of 88 recruiting on ClinicalTrials.gov ↗

Drug pipeline

Each drug at the furthest stage it has reached for this condition, from ChEMBL's drug indications

Approved 2

  • BrexanoloneGABA-A receptor; anion channel positive allosteric modulator
  • ZuranoloneGABA-A receptor; anion channel positive allosteric modulator

Phase 3 3

  • KetamineGlutamate [NMDA] receptor negative allosteric modulator
  • AripiprazoleDopamine D2 receptor partial agonist
  • CelecoxibCyclooxygenase-2 inhibitor

Phase 2 5

Phase 1 or earlier 1

How its trials ended

447 ClinicalTrials.gov studies of the condition, classified by TrialPanorama, partly automatically, so some labels are wrong

Of the 68 whose ending is known, 54% met their primary endpoint, 9% missed it and 37% stopped early.

  • Completed, result not reported20446%
  • Ongoing12428%
  • Status unknown5111%
  • Met its primary endpoint378%
  • Stopped: other or unclear153%
  • Missed its primary endpoint61%
  • Stopped: enrollment or feasibility61%
  • Stopped: sponsor or business decision2<1%
  • Stopped: funding2<1%

Trials authorized in Canada

Newest first; search them all in Canada trials
Oct 23, 2024A double-blind, randomized trial of quetiapine versus trazadone in women with postpartum depressionTrazodone / QuetiapineDr Verinder SharmaClosed
Jul 22, 2021A pilot study on the safety, tolerability, and effectiveness of quetiapine in postpartum depressionQuetiapineLawson Health Research InstituteOngoing
Sep 22, 2016Adjunctive use of celecoxib in the treatment of bipolar postpartum depression: a randomized, double-blind, placebo controlled trialCelecoxibDr Verinder SharmaPending
Jun 8, 2016A multicenter, randomized, double-blind, parallel-group, placebo-controlled study evaluating the efficacy, safety, and pharmacokinetics of SAGE-547 injection…Allopregnanolone (SAGE-547, brexanolone)Sage TherapeuticsPending

Medicines authorised in the EU

Newest first
AuthorisedMedicineHolderEPAR
not availableZurzuvaeZuranoloneBiogen Netherlands B.V.EMA ↗

Condition names come from Health Canada's trial database. Orphan designations and EU medicines are matched when their indication names the condition as whole words, so a broader or differently worded indication can be missed. Recruiting counts are live from ClinicalTrials.gov's own condition search, refreshed daily. ClinicalTrials.gov, Health Canada Clinical Trials Database, FDA orphan designations, EMA

Esc

Type a name: a tool, a company, a drug or brand, a condition, a gene or a state. Identifiers like K231234, NCT05012345 or NDA 215866 open their record.

Logos are each company's own site icon, matched by name through Wikidata, or logos provided by Logo.dev.Company names and logos identify the companies in public FDA and registry records and do not imply endorsement.